MAPT and Alzheimer disease: The high biological and physiological heterogeneity in AD related to age, sex and disease stage, and the relatively small number of AD subjects (15 FACs and 42 NFACs, all of whom received 18F-AV-1451 tau PET scans and APOE ε4 genotyping) may limit the generalizability of results from the study.